[Chemoradiotherapy of non-small-cell bronchogenic carcinoma].
Lung cancer is the worldwide most widespread tumor disease with very poor prognosis. It is the most frequent cause of death on a malignancy. Surgery remains the treatment of choice, however, it can be applied to a small number of patients who are at the time of diagnosis in the operable stage. Chemoradiotherapy can be used either as an exclusive or as a neoadjuvant treatment. This paper reviews chemoradiotherapy regiments in those two clinical situations. With exclusive chemoradiotherapy, the concomitant scheme seems to be the most favourable.
Coupek
P
P
Klinika komplexní onkologické péce-oddĕlení radiacní inkologie, Masarykův onkologický ústav, Brno. couplek@mou.cz
Seneklová
Z
Z
Perková
H
H
Kebedeová
D
D
D002283:Carcinoma, Bronchogenic / Q000188:drug therapy* / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*